A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite having low CA19-9 levels due to a genetic variation.
A new study suggests that adjusting the cutoff value for the pancreatic tumor marker, serum carbohydrate antigen 19-9 (CA19-9), could help identify additional cases of high-risk pancreatic cancer. Researchers developed a dual-threshold model for measuring CA19-9 levels in patients with suspected pancreatic disease.
This innovative approach revealed that some individuals who tested within the lower threshold range of CA19-9 may actually have advanced stages of pancreatic cancer, particularly if they carry genetic variations that affect their ability to produce this biomarker. These genetic mutations can lead to low or undetectable CA19-9 levels in patients with high-risk disease.
The findings highlight the limitations of relying solely on a single cutoff value for CA19-9 and underscore the importance of considering additional factors, such as patient genetics, when evaluating pancreatic cancer risk. By incorporating these genetic variations into diagnostic criteria, healthcare providers may be able to more accurately identify patients who require urgent intervention or further testing.
This dual-threshold model could potentially improve early detection rates and treatment outcomes for pancreatic cancer patients, particularly those with low CA19-9 levels but high-risk disease characteristics. Further research is needed to validate these results and develop standardized guidelines for implementing this approach in clinical practice.
